Codetta Biosciences

Executive Summary

Codetta Biosciences is a San Francisco-based private company developing a novel multiplex biomarker measurement platform that combines the precision of digital PCR with the dynamic range of quantitative PCR. Founded in 2019, the company aims to enable simultaneous detection of blood-based protein biomarkers and nucleic acids, targeting applications in liquid biopsy and multi-analyte diagnostics. Their proprietary approach addresses key limitations in conventional multiplexing, offering high sensitivity and broad dynamic range in a single assay. While still in early development stages with no disclosed funding or partnerships, Codetta's technology has the potential to significantly impact precision medicine by providing comprehensive biomarker panels from minimally invasive samples. The company's platform could accelerate disease monitoring, early detection, and therapy selection across oncology and beyond.

Upcoming Catalysts (preview)

• H2 2026Series A Funding Announcement70% success
• 2027First Pharma Partnership or Licensing Deal50% success
• 2026Peer-Reviewed Publication Demonstrating Platform Performance60% success